ライフサイエンスコーパス: Coats

1 Coats concentration in our NPs increased zeta potential,

2 Coats define the composition of carriers budding from or

3 Coats disease is an idiopathic, progressive disease that

4 Coats disease was the most frequent underlying cause, id

5 Coats plus (CP) can be caused by mutations in the CTC1 c

6 Coats plus is a highly pleiotropic disorder particularly

7 Coats' disease can be difficult to differentiate from re

8 Coats' disease is characterized by abnormal retinal vasc

9 Coats' disease, on the other hand, is an idiopathic, ret

10 Coats-like exudative vasculopathy, not previously report

11 Coats-like RP is distinct from Coats disease in that exu

12 Coats-like vitreoretinopathy is present in up to 5% of a

13 patients who underwent treatment for stage 2 Coats' disease in a tertiary center in the United Kingdo

14 e intraoperative FA in children with stage 2 Coats' disease led to good anatomic outcome, with preser

15 (n = 15, 22%), pars planitis (n = 14, 21%), Coats disease (n = 11, 16%), previous retinal detachment

16 After establishing the diagnosis of stage 3 Coats' disease, the patient was treated with intravitrea

17 n 1 year were most likely to have PFV (49%), Coats' disease (20%), or vitreous hemorrhage (7%); those

18 Is were obtained from records of 5 eyes of 5 Coats' patients and 29 eyes of 23 patients with retinobl

19 This case highlights the occurrence of a Coats-like response following vitreoretinal surgery for

20 consisting of a mother and four sons, with a Coats phenotype were revaluated after 25 years of clinic

21 This is the first reported family with a Coats'-type RP associated to a RPGR mutation and segrega

22 esponding to the exudates, consistent with a Coats-like response.

23 ive procedures for the treatment of advanced Coats disease.

24 s from 31 consecutive patients with advanced Coats disease at an average age of 47.8 +/- 34.2 (2-156)

25 s from 31 consecutive patients with advanced Coats disease at an average age of 47.8 34.2 (2-156) mon

26 While MR imaging of retinoblastoma and Coats' disease have been examined for differentiating fe

27 Clinical features of retinoblastoma and Coats' disease often resemble each other and can lead to

28 an important pathophysiological link between Coats plus and the clinically related telomere disorders

29 ate a previously reported family affected by Coats'-type RP without genetic diagnosis and to describe

30 Consecutive Coats patients examined between February 2012 and Januar

31 Three patients demonstrated Coats-like fundus findings at the time of RP diagnosis.

32 patients diagnosed with RP and demonstrating Coats-like exudative vitreoretinopathy were included.

33 ve vitreoretinopathy (FEVR), Norrie disease, Coats' disease, bilateral persistent fetal vasculature,

34 ening and cause a telomere biology disorder, Coats plus (CP).

35 /s) differed significantly from the mean for Coats' patients (1364 +/- 309 mm(2)/s), (P < .001).

36 Coats-like RP is distinct from Coats disease in that exudative pathologic features occu

37 older than 5 years were most likely to have Coats' disease (57%), toxocariasis (8%), or FEVR (6%).

38 2 to 5 years of age were most likely to have Coats' disease (61%), toxocariasis (8%), or PFV (7%); an

39 Most of the mononuclear cells in Coats' disease samples were CD163(+) (purple), and a min

40 adjunctive treatment to ablative therapy in Coats' disease.

41 n to the conventional ablation treatments in Coats' patients.

42 he most common pseudoretinoblastomas include Coats' disease, PFV, and vitreous hemorrhage, but the sp

43 conditions, and the 10 most common included Coats' disease (n = 244; 40%), persistent fetal vasculat

44 This case report describes a rare case of Coats disease in adult female patient with preserved vis

45 ponent, have been identified as the cause of Coats plus syndrome.

46 The classical form of Coats' disease is almost invariably isolated, unilateral

47 is CTC1 mutant and the phenotypic overlap of Coats plus with the telomeric maintenance disorders comp

48 22 years), and median age at presentation of Coats-like exudative vitreoretinopathy was 18 years (ran

49 RP diagnosis and at time of presentation of Coats-like exudative vitreoretinopathy, pedigree analysi

50 A female with a unilateral variant of Coats' disease gave birth to a son affected by Norrie di

51 ing the diagnosis when retinoblastoma and/or Coats' disease are suspected.

52 r the formation of retinal telangiectasia or Coats-like vasculopathy in patients with CRB1 mutations

53 l Eales' disease with co-existing, secondary Coats'-like reaction in a 25-year-old male exhibiting un

54 f Eales' disease with co-existing, secondary Coats'-like reaction.

55 a diagnosis of Eales' disease with secondary Coats'-like reaction was made.

56 In our study, Coats' disease, choroidal hemangioma, and nanophthalmos

57 is congenita, Hoyeraal-Hreidarsson syndrome, Coats plus syndrome and Revesz syndrome.

58 The term Coats-like RP is used colloquially to describe this dise

59 Here, we show that Coats plus results from mutations in CTC1, encoding cons

60 We suggest that Coats' telangiectasis is secondary to somatic mutation i

61 conversional methods in conjunction with the Coats-Redfern approach.

62 tional retinal detachment (TRD) secondary to Coats-like vasculopathy, persistent macular detachment a

63 We herein describe two Coats plus patients with telomere and genomic defects; b

64 Twenty children with Coats' disease who underwent intraoperative RetCam FA an

65 udy population: Children < 18 diagnosed with Coats disease or Retinoblastoma between January 1, 2018

66 hortened telomeres in three individuals with Coats plus and an increase in spontaneous gammaH2AX-posi

67 inas of nine enucleated eyes from males with Coats' disease demonstrated in one a somatic mutation in

68 es and 1 cytology sample from a patient with Coats' disease and 1 case of chronic retinal detachment

69 Patients with Coats' disease diagnosed clinically, angiographically, o

70 ences in visual acuities among patients with Coats' disease who sought treatment at a tertiary care u